ArticleEuropean journal of pediatrics2026
Clinical characteristics and predictors of severe pertussis in hospitalized children after the COVID-19 period in Türkiye: a multicenter study.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
103 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis resurged globally, after the relaxation of COVID-19 measures, underscoring its continued relevance as a public health concern, yet data remain limited on the factors associated with severe disease in children. The present study identified risk factors for severe pertussis to improve early recognition and clinical management. This multicenter retrospective study analyzed the demographic, clinical, and laboratory data of the 839 children hospitalized with laboratory-confirmed pertussis across 47 centers in Türkiye (2023-2024). Severe disease was defined as the need for respiratory support or the development of encephalopathy and/or cardiovascular dysfunction. After univariate comparison, significant variables were evaluated using center-adjusted multivariable logistic regression in vaccine-eligible (> 2 months) and non-eligible (≤ 2 months) groups. The patient's median age was 2 months (IQR 1.5-5.0), and 77.8% were younger than 6 months. Severe disease occurred in 26.1% of cases. In univariate analysis, younger age, vaccine refusal, refugee status, feeding difficulties, apnea, respiratory distress, leukocytosis, viral co-infection, and abnormal chest X-ray findings at admission were associated with severe disease. In infants ≤ 2 months, apnea (OR = 3.74; p < 0.001), respiratory distress (OR = 5.48; p < 0.001), and WBC count (OR = 1.035 per 1 × 10
Indexed as
Identifiers
42448840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.